Hong Kong's ORI hits first close on Fund II, exits Kymab
Hong Kong healthcare-focused VC firm ORI Capital has reached a first close of $112 million on its second fund and exited its largest investment, UK biotech developer Kymab, as part of a $1.1 billion deal.
A second close that would take Fund II past 50% of its $400 million target is currently being finalized, according to a source familiar with the situation. A third close is expected by the end of 2021....
More on Greater China
Latest News
Deal focus: Monetizing mice
ORI Capital’s 2.8x return on its investment in Kymab was in part based on helping the company make the transition from antibody-based discovery platform to drug development engine
Prosus leads $30m Series C for India agtech start-up
Prosus Ventures, formerly a VC arm of South African media conglomerate Naspers, has led a $30 million Series C round for Indian agricultural technology provider DeHaat.
Fund focus: Endiya sees India’s early-stage upside
Having scaled up in fund size to $75 million for its second vintage, Endiya Partners is looking for opportunities in an increasingly attractive yet competitive Indian start-up ecosystem
Monument Group recruits Japan representative
Placement agent Monument Group has appointed Hiroshi Nishimuro, formerly of Morgan Stanley, as its Japan representative to lead fundraising efforts and manage GP relationships in the country.